About Kadmon (NYSE:KDMN)
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.
Industry, Sector and Symbol
Trailing P/E Ratio-2.05714285714286
Forward P/E Ratio-2.22
Sales & Book Value
Annual Sales$26.06 million
Price / Sales10.86
Price / CashN/A
Book Value($1.41) per share
Price / Book-2.55
Return on EquityN/A
Return on Assets-124.91%
Kadmon (NYSE:KDMN) Frequently Asked Questions
What is Kadmon's stock symbol?
Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."
How were Kadmon's earnings last quarter?
Kadmon Holdings Inc (NYSE:KDMN) issued its quarterly earnings data on Thursday, November, 9th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by $0.04. The company had revenue of $2.28 million for the quarter, compared to analyst estimates of $5.69 million. The firm's quarterly revenue was down 60.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($4.24) EPS. View Kadmon's Earnings History.
Where is Kadmon's stock going? Where will Kadmon's stock price be in 2018?
5 brokerages have issued 12-month price objectives for Kadmon's shares. Their forecasts range from $3.00 to $25.00. On average, they anticipate Kadmon's stock price to reach $11.40 in the next twelve months. View Analyst Ratings for Kadmon.
Who are some of Kadmon's key competitors?
Some companies that are related to Kadmon include Sinovac Biotech (SVA), ChemoCentryx (CCXI), 3SBio (SSRX), Strongbridge Biopharma (SBBP), Syros Pharmaceuticals (SYRS), Synlogic (SYBX), Vericel (VCEL), Syndax Pharmaceuticals (SNDX), Mereo BioPharma Group (MPH), Kamada (KMDA), Fortress Biotech (FBIO), Catalyst Biosciences (CBIO), Mediwound (MDWD), KalVista Pharmaceuticals (KALV), Avid Bioservices (CDMO), Alimera Sciences (ALIM), VIVUS (VVUS) and Cardiome Pharma (CRME).
When did Kadmon IPO?
(KDMN) raised $101 million in an initial public offering on Wednesday, July 27th 2016. The company issued 5,600,000 shares at $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.
Who owns Kadmon stock?
Kadmon's stock is owned by many different of institutional and retail investors. Top institutional shareholders include
GOLDENTREE ASSET MANAGEMENT LP
(7.20%), Goldentree Asset Management LP (2.05%), Crestline Management LP (0.71%), Linden Advisors LP (0.67%), AE Wealth Management LLC (0.66%) and Geode Capital Management LLC (0.59%). Company insiders that own Kadmon stock include Bart M Schwartz, Daniel S Loeb, Eugene Bauer, Goldentree Asset Management Lp, Harlan Waksal, Konstantin Poukalov and Steven N Gordon. View Institutional Ownership Trends for Kadmon.
Who sold Kadmon stock? Who is selling Kadmon stock?
Kadmon's stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Linden Advisors LP, Millennium Management LLC and Crestline Management LP. View Insider Buying and Selling for Kadmon.
Who bought Kadmon stock? Who is buying Kadmon stock?
Kadmon's stock was acquired by a variety of institutional investors in the last quarter, including Goldentree Asset Management LP, Geode Capital Management LLC, Spark Investment Management LLC, Sawtooth Solutions LLC, AE Wealth Management LLC, BlackRock Inc., BlueCrest Capital Management Ltd and Wells Fargo & Company MN. Company insiders that have bought Kadmon stock in the last two years include Bart M Schwartz, Daniel S Loeb, Eugene Bauer, Goldentree Asset Management Lp, Harlan Waksal, Konstantin Poukalov and Steven N Gordon. View Insider Buying and Selling for Kadmon.
How do I buy Kadmon stock?
Shares of Kadmon can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kadmon's stock price today?
One share of Kadmon stock can currently be purchased for approximately $3.60.
How big of a company is Kadmon?
Kadmon has a market capitalization of $283.12 million and generates $26.06 million in revenue each year. The company earns $-208,750,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. Kadmon employs 118 workers across the globe.
How can I contact Kadmon?
Kadmon's mailing address is 450 E 29th St, NEW YORK, NY 10016-8367, United States. The company can be reached via phone at +1-212-3086000 or via email at [email protected]
MarketBeat Community Rating for Kadmon (KDMN)MarketBeat's community ratings are surveys of what our community members think about Kadmon and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Kadmon (NYSE:KDMN) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Buy|
|Consensus Rating Score: ||2.40||2.25||2.25||2.67|
|Ratings Breakdown: ||1 Sell Rating(s)|
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$11.40||$9.75||$9.75||$9.85|
|Price Target Upside: ||146.22% upside||172.35% upside||164.23% upside||322.75% upside|
Kadmon (NYSE:KDMN) Consensus Price Target History
Kadmon (NYSE:KDMN) Analyst Ratings History
(Data available from 2/22/2016 forward)
Kadmon (NYSE:KDMN) Earnings History and Estimates Chart
Kadmon (NYSE KDMN) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017||Q3 2017||($0.38)||($0.42)||$5.69 million||$2.28 million||View||N/A|
|8/3/2017||Q2 2017||($0.49)||($0.44)||$3.46 million||$3.00 million||View||N/A|
|5/15/2017||Q1 2017||($0.52)||($0.39)||$4.25 million||$5.60 million||View||N/A|
|3/22/2017||Q4 2016||($0.71)||($0.50)||$4.50 million||$4.28 million||View||N/A|
|11/9/2016||Q3 2016||($0.40)||($4.23)||$3.90 million||$5.70 million||View||N/A|
|9/7/2016||Q2 2016||($0.88)||($4.42)||$6.48 million||$6.42 million||View||N/A|
Kadmon (NYSE:KDMN) Earnings Estimates
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Kadmon (NYSE:KDMN)
No dividend announcements for this company have been tracked by MarketBeat.com
Kadmon (NYSE KDMN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.41%
Institutional Ownership Percentage: 53.27%
Kadmon (NYSE KDMN) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|9/6/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||302,950||$2.73||$827,053.50|| |
|8/10/2017||Harlan Waksal||CEO||Buy||5,000||$2.27||$11,350.00||110,747|| |
|8/8/2017||Eugene Bauer||Director||Buy||5,000||$2.36||$11,800.00||1,716|| |
|8/8/2017||Harlan Waksal||CEO||Buy||3,707||$2.34||$8,674.38||105,747|| |
|8/8/2017||Steven N. Gordon||VP||Buy||1,000||$2.47||$2,470.00|| |
|7/31/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||349,661||$2.60||$909,118.60|| |
|7/11/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||34,462||$3.69||$127,164.78|| |
|6/29/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||64,375||$4.04||$260,075.00|| |
|6/27/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||108,827||$3.69||$401,571.63|| |
|6/26/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||515,643||$3.51||$1,809,906.93|| |
|6/22/2017||Goldentree Asset Management Lp||Major Shareholder||Sell||767,363||$3.50||$2,685,770.50|| |
|3/13/2017||Daniel S Loeb||Major Shareholder||Buy||1,488,095||$3.36||$4,999,999.20|| |
|11/16/2016||Harlan Waksal||CEO||Buy||2,000||$6.37||$12,740.00||102,040|| |
|11/14/2016||Harlan Waksal||CEO||Buy||2,000||$6.79||$13,580.00||100,040|| |
|11/11/2016||Konstantin Poukalov||CFO||Buy||4,000||$5.81||$23,240.00||1,000|| |
|9/14/2016||Daniel S Loeb||Major Shareholder||Buy||19,611||$7.79||$152,769.69|| |
|9/13/2016||Daniel S Loeb||Major Shareholder||Buy||68,654||$8.33||$571,887.82|| |
|9/6/2016||Daniel S Loeb||Major Shareholder||Buy||81,781||$9.39||$767,923.59|| |
|8/26/2016||Daniel S Loeb||Major Shareholder||Buy||32,916||$9.98||$328,501.68|| |
|8/22/2016||Daniel S Loeb||Major Shareholder||Buy||11,305||$10.00||$113,050.00|| |
|8/15/2016||Daniel S Loeb||Major Shareholder||Buy||6,010||$9.95||$59,799.50|| |
|8/12/2016||Daniel S Loeb||Major Shareholder||Buy||87,529||$9.98||$873,539.42|| |
|8/5/2016||Daniel S Loeb||Major Shareholder||Buy||66,828||$9.94||$664,270.32|| |
|8/3/2016||Daniel S Loeb||Major Shareholder||Buy||1,431,996||$11.35||$16,253,154.60|| |
|8/1/2016||Goldentree Asset Management Lp||Major Shareholder||Buy||208,333||$12.00||$2,499,996.00|| |
|7/28/2016||Bart M Schwartz||Director||Buy||2,000||$9.77||$19,540.00||26,211|| |
Kadmon (NYSE KDMN) News Headlines
|Kadmon (KDMN) PT Raised to $16.00 at Jefferies Group|
www.americanbankingnews.com - February 18 at 8:10 PM
|$3.72 Million in Sales Expected for Kadmon Holdings Inc (KDMN) This Quarter|
www.americanbankingnews.com - February 17 at 6:42 AM
|Kadmon Holdings Inc to Post FY2021 Earnings of ($2.83) Per Share, Jefferies Group Forecasts (KDMN)|
www.americanbankingnews.com - February 15 at 4:10 PM
|-$0.34 EPS Expected for Kadmon Holdings Inc (KDMN) This Quarter|
www.americanbankingnews.com - February 15 at 11:10 AM
|Kadmon (KDMN) Reports Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary Fibrosis|
www.streetinsider.com - February 14 at 9:07 AM
|Why Molina Healthcare, Brighthouse Financial, and Kadmon Holdings Slumped Today|
finance.yahoo.com - February 14 at 9:07 AM
|Why Karmon's "Positive" Data Turned Into a 21% Decline|
finance.yahoo.com - February 14 at 9:07 AM
|Vertex Pharmaceuticals, Kadmon Holdings Are Early Week Biotech Movers|
finance.yahoo.com - February 13 at 4:28 PM
|Kadmon (KDMN) Receives "Positive" Rating from Piper Jaffray Companies|
www.americanbankingnews.com - February 13 at 11:12 AM
|BRIEF-Kadmon Posts Positive Topline Results From Phase 2 Study Of KD025 In Idiopathic Pulmonary Fibrosis|
www.reuters.com - February 13 at 9:05 AM
|After-Hours Stock Movers 02/12: (KDMN) (VIPS) (RNG) Higher; (HMNY) (AFMD) (moh) Lower (more...)|
www.streetinsider.com - February 13 at 9:05 AM
|Kadmon to Host Webcast and Conference Call to Discuss Topline Results of KD025 in IPF|
finance.yahoo.com - February 13 at 9:05 AM
|Kadmon Announces Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary Fibrosis|
finance.yahoo.com - February 12 at 4:34 PM
|Major Biopharma Catalysts on February’s FDA Calendar|
247wallst.com - February 3 at 9:01 AM
|Kadmon Holdings Inc (KDMN) Receives Average Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - February 2 at 7:22 PM
|Kadmon Holdings Inc (KDMN) to Post FY2022 Earnings of ($1.58) Per Share, Jefferies Group Forecasts|
www.americanbankingnews.com - January 29 at 9:10 AM
|Kadmon Holdings (KDMN) Jumps: Stock Rises 9.3% - Nasdaq|
www.nasdaq.com - January 15 at 4:13 PM
|Kadmon Holdings (KDMN) Jumps: Stock Rises 9.3%|
finance.yahoo.com - January 15 at 10:33 AM
|Kadmon (KDMN) Lifted to "Buy" at Zacks Investment Research|
www.americanbankingnews.com - January 14 at 8:10 PM
|Reviewing Alimera Sciences (ALIM) and Kadmon (KDMN)|
www.americanbankingnews.com - January 14 at 7:34 AM
|Kadmon Holdings Inc (KDMN) Expected to Announce Earnings of -$0.34 Per Share|
www.americanbankingnews.com - January 12 at 1:04 PM
|Kadmon Holdings Inc (KDMN) Given Consensus Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - January 8 at 10:02 PM
|KDMN And 10 Other Biotech Stocks You Should Watch This Month|
www.nasdaq.com - January 2 at 4:51 PM
|$4.07 Million in Sales Expected for Kadmon Holdings Inc (KDMN) This Quarter|
www.americanbankingnews.com - December 28 at 2:12 AM
|Kadmon Holdings Inc (KDMN) to Post FY2017 Earnings of ($1.73) Per Share, Jefferies Group Forecasts|
www.americanbankingnews.com - December 25 at 2:28 AM
|Financial Analysis: Novus Therapeutics (NVUS) & Kadmon (KDMN)|
www.americanbankingnews.com - December 23 at 3:07 AM
|ETFs with exposure to Kadmon Holdings, Inc. : December 20, 2017|
finance.yahoo.com - December 20 at 4:10 PM
|Syndax Pharmaceuticals (SNDX) versus Kadmon (KDMN) Financial Analysis|
www.americanbankingnews.com - December 20 at 11:28 AM
|Kadmon (KDMN) Stock Rating Reaffirmed by HC Wainwright|
www.americanbankingnews.com - December 15 at 2:56 PM
|Kadmon Holdings, Inc. (KDMN) Given Consensus Rating of "Hold" by Brokerages|
www.americanbankingnews.com - December 14 at 11:58 PM
|Kadmon (KDMN) & The Competition Head to Head Review|
www.americanbankingnews.com - December 14 at 7:16 AM
|Kadmon (KDMN) versus Its Peers Critical Comparison|
www.americanbankingnews.com - December 12 at 11:07 AM
|Head-To-Head Survey: Kadmon (KDMN) & Its Rivals|
www.americanbankingnews.com - December 12 at 7:56 AM
|Kadmon (KDMN) Announces Updated Positive Phase 2 Data on KD025 in cGVHD - StreetInsider.com|
www.streetinsider.com - December 11 at 11:27 AM
|Zacks: Analysts Expect Kadmon Holdings, Inc. (KDMN) Will Post Quarterly Sales of $4.07 Million|
www.americanbankingnews.com - December 11 at 10:52 AM
|Kadmon (KDMN) versus Its Peers Financial Contrast|
www.americanbankingnews.com - December 10 at 11:32 PM
|Kadmon Presents Updated Positive Phase 2 Data on KD025 in cGVHD at ASH Annual Meeting|
finance.yahoo.com - December 10 at 10:34 AM
|-$0.34 EPS Expected for Kadmon Holdings, Inc. (KDMN) This Quarter|
www.americanbankingnews.com - December 9 at 9:30 AM
|Kadmon (KDMN) & Its Rivals Critical Review|
www.americanbankingnews.com - December 5 at 3:32 AM
|Head to Head Survey: Baxalta (BXLT) vs. Kadmon (KDMN)|
www.americanbankingnews.com - December 1 at 11:38 AM
|ETFs with exposure to Kadmon Holdings, Inc. : November 30, 2017|
finance.yahoo.com - November 30 at 4:11 PM
|Financial Comparison: Kadmon (KDMN) and The Competition|
www.americanbankingnews.com - November 30 at 3:36 PM
|Kadmon Holdings, Inc. :KDMN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017|
finance.yahoo.com - November 29 at 10:52 AM
|Kadmon to Present at the 29th Annual Piper Jaffray Healthcare Conference|
finance.yahoo.com - November 27 at 5:15 PM
|Analyzing Kadmon (KDMN) and Its Peers|
www.americanbankingnews.com - November 27 at 5:28 AM
|Kadmon Holdings (KDMN) vs. Its Peers Critical Survey|
www.americanbankingnews.com - November 25 at 9:26 AM
|$4.07 Million in Sales Expected for Kadmon Holdings, Inc. (KDMN) This Quarter|
www.americanbankingnews.com - November 23 at 10:34 AM
|Reviewing Kadmon Holdings (KDMN) and 3SBio (SSRX)|
www.americanbankingnews.com - November 22 at 7:42 PM
|Head to Head Contrast: Kadmon Holdings (KDMN) vs. Its Peers|
www.americanbankingnews.com - November 22 at 3:42 PM
|Kadmon Holdings, Inc. (KDMN) Upgraded to "Hold" by Zacks Investment Research|
www.americanbankingnews.com - November 22 at 12:56 AM
Kadmon (NYSE:KDMN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Kadmon (NYSE:KDMN) Income Statement, Balance Sheet and Cash Flow Statement
Kadmon (NYSE KDMN) Stock Chart for Thursday, February, 22, 2018